已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis

特发性肺纤维化 溶血磷脂酸 任天堂 肺活量 吡非尼酮 纤维化 医学 自交轴蛋白 内科学 肺 肺功能 扩散能力 受体
作者
Amit Taneja,Garrit Jentsch,Stéphane Delage,Matthew J. Randall,Bernt van den Blink,Yasmina Bauer,Florence Namour
出处
期刊:Clinical Pharmacology & Therapeutics [Wiley]
卷期号:115 (3): 606-615 被引量:11
标识
DOI:10.1002/cpt.3138
摘要

Autotaxin (ATX) contributes to the production of lysophosphatidic acid (LPA), which is associated with fibrosis development in idiopathic pulmonary fibrosis (IPF). The ATX inhibitor ziritaxestat failed to reduce decline in forced vital capacity (FVC) in patients with IPF in ISABELA 1 and 2 (NCT03711162 and NCT03733444), two identically designed phase III studies. In the current analysis, we evaluated pharmacokinetic and pharmacodynamic data from the pooled ISABELA studies to determine whether the lack of efficacy could be attributed to insufficient exposure and/or target engagement. Nonlinear mixed effect modeling was performed to predict ziritaxestat exposure in individual patients and describe its effect on LPA C18:2 levels. We assessed whether there was a correlation between ziritaxestat and ATX concentration and evaluated the relationship between LPA C18:2 reduction and change from baseline in FVC. Ziritaxestat exposure in patients with IPF was numerically lower in those who received ziritaxestat on top of pirfenidone than in those who received ziritaxestat on top of nintedanib or ziritaxestat alone. In most patients, LPA C18:2 reduction was comparable to that reported in healthy volunteers. ATX concentrations increased over time and correlated weakly with ziritaxestat exposure and LPA C18:2 reduction. No correlation between reduction in LPA C18:2 and change from baseline in FVC was apparent. Based on these evaluations, exposure and target engagement are not thought to have contributed to the lack of efficacy observed. We hypothesize that the lack of efficacy of ziritaxestat in the ISABELA program, despite adequate LPA reduction, could be due to the involvement of an alternative pro-fibrotic pathway.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陈陈潇完成签到,获得积分20
刚刚
刚刚
xr完成签到,获得积分10
1秒前
2秒前
踏实乐枫发布了新的文献求助10
5秒前
xr发布了新的文献求助10
6秒前
6秒前
7秒前
7秒前
8秒前
粗心的小鸽子完成签到,获得积分10
8秒前
跳跃的正豪完成签到,获得积分10
9秒前
yao发布了新的文献求助10
9秒前
gbh完成签到 ,获得积分20
11秒前
子皿发布了新的文献求助10
11秒前
ccccc完成签到 ,获得积分10
12秒前
moriaty发布了新的文献求助20
13秒前
自信的寄松完成签到 ,获得积分10
15秒前
专注的夜天完成签到,获得积分10
19秒前
gzghgzh完成签到,获得积分10
20秒前
菲菲完成签到 ,获得积分10
21秒前
科研通AI6.4的应助被开朗向彤采纳,获得10
22秒前
顾矜的应助被科研通管家采纳,获得10
23秒前
Owen的应助被科研通管家采纳,获得10
23秒前
彭于晏的应助被科研通管家采纳,获得10
23秒前
vc驳回了Maestro_S的应助
23秒前
桐桐的应助被科研通管家采纳,获得10
23秒前
JamesPei的应助被科研通管家采纳,获得10
23秒前
FashionBoy的应助被科研通管家采纳,获得10
24秒前
bkagyin的应助被科研通管家采纳,获得10
24秒前
24秒前
DW的应助被科研通管家采纳,获得10
24秒前
24秒前
24秒前
FashionBoy的应助被科研通管家采纳,获得10
24秒前
笙笙的应助被科研通管家采纳,获得10
24秒前
王世缘完成签到,获得积分10
25秒前
英俊的铭的应助被DW采纳,获得10
26秒前
水煮电吹风的应助被gzghgzh采纳,获得10
27秒前
无问西东完成签到 ,获得积分10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184917
求助须知:如何正确求助?哪些是违规求助? 9573843
关于积分的说明 21833352
捐赠科研通 7782304
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082